Managing complex perianal fistulizing disease.

Pederson KE, Lightner AL. J Laparoendosc Adv Surg Tech A. 2021;31(8):890-897.

Fistulizing Crohn's disease.

Lightner AL, Ashburn JH, Brar MS, et al. Curr Probl Surg. 2020;57(11):100808.

Management of complex perianal Crohn's disease.

Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, et al. Ann Gastroenterol. 2017;30(1):33-44.

Modern surgical strategies for perianal Crohn's disease.

Zabot GP, Cassol O, Saad-Hossne R, et al. World J Gastroenterol. 2020; 26(42):6572-6581.

Development and initial psychometric validation of a patient-reported outcome measure for Crohn's perianal fistula: the Crohn's anal fistula quality of life (CAF-QoL) scale.

Adegbola SO, Dibley L, Sahnan K, et al. Gut. 2021;70(9):1649-1656.

Treatment algorithms for Crohn's disease.

Sulz MC, Burri E, Michetti P, et al. Digestion. 2020;101(suppl 1):43-57.

Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists

Agrawal M, Spencer EA, Colombel JF, et al. Gastroenterology. 2021;161(1):47-65.

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease.

Ji CC, Takano S. Intest Res. 2017;15(2):182-186.

Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn's disease: ENTERPRISE Study.

Schwartz DA, Peyrin-Biroulet L, Lasch K, et al. Clin Gastroenterol Hepatol. 2022;20(5):1059-1067.

Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.

Ayoub F, Odenwald M, Micic D, et al. Intest Res. 2022;20(2):240-250.

Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature.

Attauabi M, Burisch J, Seidelin JB. Scand J Gastroenterol. 2021;56(1):53-58.

Mesenchymal stromal cell therapy in the management of perianal fistulas in Crohn's disease: an up-to-date review.

Gallo G, Tiesi V, Fulginiti S, et al. Medicina (Kaunas). 2020;56(11):563.

Regenerative medicine for digestive fistulae therapy: benefits, challenges and promises of stem/stromal cells and emergent perspectives via their extracellular vesicles.

Sebbagh AC, Rosenbaum B, Péré G, et al. Adv Drug Deliv Rev. 2021;179:113841.

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

Panés J, García-Olmo D, Van Assche G, et al. Lancet. 2016;388(10051):1281-1290.

Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn's disease: ADMIRE-CD phase 3 randomized controlled trial.

Garcia-Olmo D, Gilaberte I, Binek M, et al. Dis Colon Rectum. 2022;65(5):713-720.

P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s disease and complex perianal fistulas.

Zmora O, Baumgart DC, Faubion W, et al. J Crohn's Colitis. 2022;16(suppl 1):i536-i537.

Patient Resources

American College of Gastroenterology

American Gastroenterological Association

Crohn's and Colitis Foundation

European Crohn's and Colitis Organisation

National Institute of Diabetes and Digestive and Kidney Diseases

Health information for Crohn's disease